Itraconazole: Difference between revisions
(Restore original dosing content alongside dynamic SMW tables) |
|||
| (9 intermediate revisions by 6 users not shown) | |||
| Line 3: | Line 3: | ||
*Dosage Forms: Capsule, solution (for oropharyngeal/esophageal candida) | *Dosage Forms: Capsule, solution (for oropharyngeal/esophageal candida) | ||
*Routes of Administration: | *Routes of Administration: | ||
*Common Trade Names: | *Common Trade Names: Sporanox, Sporaz, Orungal | ||
==Adult Dosing== | ==Adult Dosing== | ||
*200mg PO 1-4 times per day | *200mg PO 1-4 times per day | ||
===Indications by Disease=== | |||
{{#ask: [[Has DrugName::Itraconazole]] [[Has Population::Adult]] | |||
|?Treats disease=Disease | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|format=table | |||
|limit=50 | |||
|mainlabel=- | |||
|headers=show | |||
|sort=Treats disease | |||
}} | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
* > 5y: 2.5-10mg/kg 2-3 times per day | *> 5y: 2.5-10mg/kg 2-3 times per day | ||
===Indications by Disease=== | |||
{{#ask: [[Has DrugName::Itraconazole]] [[Has Population::Pediatric]] | |||
|?Treats disease=Disease | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|format=table | |||
|limit=50 | |||
|mainlabel=- | |||
|headers=show | |||
|sort=Treats disease | |||
}} | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | ||
| Line 26: | Line 52: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*CHF, pulmonary edema | *[[CHF]], pulmonary edema | ||
*Hepatotoxicity | *Hepatotoxicity | ||
*SJS/TEN | *SJS/TEN | ||
*Pancreatitis | *[[Pancreatitis]] | ||
===Common=== | ===Common=== | ||
*Nausea/vomiting, diarrhea, abdominal pain | *Nausea/vomiting, diarrhea, abdominal pain | ||
| Line 39: | Line 65: | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: 32-96h | *Half-life: 32-96h | ||
*Metabolism: Hepatic, P450 CYP3A4 | *Metabolism: Hepatic, [[P450]] CYP3A4 | ||
*Excretion: | *Excretion: Urine, Feces | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
| Line 47: | Line 73: | ||
==See Also== | ==See Also== | ||
*[[Antifungals]] | |||
*[[Fungal infections]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:ID]] | |||
Latest revision as of 02:38, 20 March 2026
Administration
- Type: Antifungal
- Dosage Forms: Capsule, solution (for oropharyngeal/esophageal candida)
- Routes of Administration:
- Common Trade Names: Sporanox, Sporaz, Orungal
Adult Dosing
- 200mg PO 1-4 times per day
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Cryptococcosis | 200mg PO q12hrs x 6-12 months | Pulmonary not AIDS associated alt |
Pediatric Dosing
- > 5y: 2.5-10mg/kg 2-3 times per day
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Tinea capitis | 3-5mg/kg PO daily (max 400mg) x 4-6 weeks | Second line |
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
Renal Dosing
- Adult: No adjustment
- Pediatric:
Hepatic Dosing
- Adult: No adjustment
- Pediatric:
Contraindications
- Allergy to class/drug
- Concomitant use of CYP3A4 substrates (e.g. ergots, lurasidone, methadone, oral midazolam, simvastatin, ticagrelor, and triazolam)
- Ventricular dysfunction (relative)
Adverse Reactions
Serious
- CHF, pulmonary edema
- Hepatotoxicity
- SJS/TEN
- Pancreatitis
Common
- Nausea/vomiting, diarrhea, abdominal pain
- Headache, dizziness
- Edema
- Pruritus, rash
- URI symptoms
Pharmacology
- Half-life: 32-96h
- Metabolism: Hepatic, P450 CYP3A4
- Excretion: Urine, Feces
Mechanism of Action
- Inhibits synthesis of ergosterol (fungal cell membrane component)